Identification of free fatty acid receptor 2 agonists using virtual screening.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 28 05 2020
revised: 24 07 2020
accepted: 31 07 2020
pubmed: 7 8 2020
medline: 23 6 2021
entrez: 7 8 2020
Statut: ppublish

Résumé

Structure- and ligand-based virtual-screening methods (docking, 2D- and 3D-similarity searching) were analyzed for their effectiveness in virtual screening against FFAR2. To evaluate the performance of these methods, retrospective virtual screening was performed. Statistical quality of the methods was evaluated by BEDROC and RIE. The results revealed that electrostatic similarity search protocol using EON (ET combo) outperformed all other protocols with outstanding enrichment of >95% in top 1% and 2% of the dataset with an AUC of 0.958. Interestingly, the hit lists that are obtained from different virtual-screening methods are generally highly complementary to hits found from electrostatic similarity searching. These results suggest that considering electrostatic similarity searching first increases the chance of identifying more (and more diverse) active compounds from a virtual-screening campaign. Accordingly, prospective virtual screening using electrostatic similarity searching was used to identify novel FFAR2 ligands. The discovered compounds provide new chemical matter starting points for the initiation of a medicinal chemistry campaign.

Identifiants

pubmed: 32755680
pii: S0960-894X(20)30571-0
doi: 10.1016/j.bmcl.2020.127460
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
FFA2R protein, human 0
Ligands 0
Receptors, Cell Surface 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127460

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

James I Fells (JI)

Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: james.fells@merck.com.

Xi Ai (X)

Merck & Co., Inc., Kenilworth, NJ, USA.

Adam Weinglass (A)

Merck & Co., Inc., Kenilworth, NJ, USA.

Wen Feng (W)

Merck & Co., Inc., Kenilworth, NJ, USA.

Ying Lei (Y)

Merck & Co., Inc., Kenilworth, NJ, USA.

Michael Finley (M)

Merck & Co., Inc., Kenilworth, NJ, USA.

Hamid R Hoveyda (HR)

Euroscreen SA, 47, rue Adrienne Bolland, 6041 Gosselies, Belgium.

Graeme L Fraser (GL)

Euroscreen SA, 47, rue Adrienne Bolland, 6041 Gosselies, Belgium.

Michelle Machacek (M)

Merck & Co., Inc., Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH